Daniela Meco1, Tiziana Servidei1, Giuseppe Lamorte1, Elena Binda1, Vincenzo Arena1, Riccardo Riccardi1. 1. Department of Pediatric Oncology, Catholic University, Rome, Italy (D.M., T.S., R.R.); Istituto CSS - Mendel Laboratory, Rome, Italy (G.L.); Department of Biotechnology and Biosciences, Building U3, University of Milan Bicocca, Milan, Italy (E.B.); Institute of Pathology, Catholic University, Rome, Italy (V.A.).
Abstract
BACKGROUND: Ependymoma management remains challenging because of the inherent chemoresistance of this tumor. To determine whether ependymoma stem cells (SCs) might contribute to therapy resistance, we investigated the sensitivity of ependymoma SCs to temozolomide and etoposide. METHODS: The efficacies of the two DNA damaging agents were explored in two ependymoma SC lines in vitro and in vivo models. RESULTS: Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomide impaired tumor-initiation properties. Consistently, temozolomide but not etoposide showed significant antitumoral activity on ependymoma SC-driven subcutaneous and orthotopic xenografts by reducing the mitotic fraction. In vitro temozolomide at the EC50 (10 µM) induced accumulation of cells in the G2/M phase that was unexpectedly accompanied by downregulation of p27 and p21 without modulation of full-length p53 (FLp53). Differentiation-committed ependymoma SCs acquired resistance to temozolomide. Inhibition of proliferation was partly due to apoptosis, that occurred earlier in differentiated cells as compared to neurospheres. The activation of apoptosis correlated with an increase in p53β/γ isoforms without modulation of FLp53 under both serum-free and differentiation-promoting media. Incubation of cells in both conditions with temozolomide resulted in increased glioneuronal differentiation exhibiting elevated glial fibrillary acidic protein, galactosylceramidase, and βIII-tubulin expression compared to untreated controls. O(6)-methylguanine DNA methyltransferase (MGMT) transcript levels were very low in SCs, and were increased by treatment and, epigenetically, by differentiation through MGMT promoter unmethylation. CONCLUSION: Ependymoma growth might be impaired by temozolomide through preferential depletion of a less differentiated, more tumorigenic, MGMT-negative cell population with stem-like properties.
BACKGROUND:Ependymoma management remains challenging because of the inherent chemoresistance of this tumor. To determine whether ependymoma stem cells (SCs) might contribute to therapy resistance, we investigated the sensitivity of ependymoma SCs to temozolomide and etoposide. METHODS: The efficacies of the two DNA damaging agents were explored in two ependymoma SC lines in vitro and in vivo models. RESULTS:Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomideimpaired tumor-initiation properties. Consistently, temozolomide but not etoposide showed significant antitumoral activity on ependymoma SC-driven subcutaneous and orthotopic xenografts by reducing the mitotic fraction. In vitro temozolomide at the EC50 (10 µM) induced accumulation of cells in the G2/M phase that was unexpectedly accompanied by downregulation of p27 and p21 without modulation of full-length p53 (FLp53). Differentiation-committed ependymoma SCs acquired resistance to temozolomide. Inhibition of proliferation was partly due to apoptosis, that occurred earlier in differentiated cells as compared to neurospheres. The activation of apoptosis correlated with an increase in p53β/γ isoforms without modulation of FLp53 under both serum-free and differentiation-promoting media. Incubation of cells in both conditions with temozolomide resulted in increased glioneuronal differentiation exhibiting elevated glial fibrillary acidic protein, galactosylceramidase, and βIII-tubulin expression compared to untreated controls. O(6)-methylguanine DNA methyltransferase (MGMT) transcript levels were very low in SCs, and were increased by treatment and, epigenetically, by differentiation through MGMT promoter unmethylation. CONCLUSION:Ependymoma growth might be impaired by temozolomide through preferential depletion of a less differentiated, more tumorigenic, MGMT-negative cell population with stem-like properties.
Authors: F Nemati; A Livartowski; P De Cremoux; Y Bourgeois; F Arvelo; P Pouillart; M F Poupon Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: Dora B Bocangel; Sydney Finkelstein; S Clifford Schold; Kishor K Bhakat; Sankar Mitra; Demetrius M Kokkinakis Journal: Clin Cancer Res Date: 2002-08 Impact factor: 12.531
Authors: Charles Teo; Peter Nakaji; Patricia Symons; Vivienne Tobias; Richard Cohn; Robert Smee Journal: Childs Nerv Syst Date: 2003-05-22 Impact factor: 1.475
Authors: Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky Journal: Br J Cancer Date: 2003-04-07 Impact factor: 7.640
Authors: Amr H Saleh; Nardin Samuel; Kyle Juraschka; Mohammad H Saleh; Michael D Taylor; Michael G Fehlings Journal: Nat Rev Cancer Date: 2022-01-14 Impact factor: 69.800
Authors: Mark Barszczyk; Pawel Buczkowicz; Pedro Castelo-Branco; Stephen C Mack; Vijay Ramaswamy; Joshua Mangerel; Sameer Agnihotri; Marc Remke; Brian Golbourn; Sanja Pajovic; Cynthia Elizabeth; Man Yu; Betty Luu; Andrew Morrison; Jennifer Adamski; Kathleen Nethery-Brokx; Xiao-Nan Li; Timothy Van Meter; Peter B Dirks; James T Rutka; Michael D Taylor; Uri Tabori; Cynthia Hawkins Journal: Acta Neuropathol Date: 2014-08-06 Impact factor: 17.088
Authors: Rebecca Lewis; Yuping D Li; Lindsey Hoffman; Rintaro Hashizume; Gordan Gravohac; Gavin Rice; Nitin R Wadhwani; Chunfa Jie; Tatiana Pundy; Barbara Mania-Farnell; Chandra S Mayanil; Marcelo B Soares; Ting Lei; Charles D James; Nicolas K Foreman; Tadanori Tomita; Guifa Xi Journal: Neoplasia Date: 2019-04-18 Impact factor: 5.715
Authors: Lorena Favaro Pavon; David Capper; Tatiana Tais Sibov; Silvia Regina Caminada de Toledo; Ulrich-W Thomale; Jean Gabriel de Souza; Francisco Romero Cabral; Carolina Maria Berra; Marcos Devanir Silva da Costa; Jardel Mendonça Niçacio; Patrícia Alessandra Dastoli; Daniela Mara de Oliveira; Suzana M F Malheiros; Edgar Ferreira da Cruz; Jackeline Moraes Malheiros; Sérgio Mascarenhas de Oliveira; Nasjla Saba Silva; Antonio Sérgio Petrilli; Andrea Maria Cappellano; Milena Colò Brunialti; Reinaldo Salomão; Manoel A de Paiva Neto; Ana Marisa Chudzinski-Tavassi; Sérgio Cavalheiro Journal: Sci Rep Date: 2019-07-10 Impact factor: 4.379
Authors: Lorena Favaro Pavon; Tatiana Tais Sibov; Silvia Regina Caminada de Toledo; Daniela Mara de Oliveira; Francisco Romero Cabral; Jean Gabriel de Souza; Pamela Boufleur; Luciana C Marti; Jackeline Moraes Malheiros; Edgar Ferreira da Cruz; Fernando F Paiva; Suzana M F Malheiros; Manoel A de Paiva Neto; Alberto Tannús; Sérgio Mascarenhas de Oliveira; Nasjla Saba Silva; Andrea Maria Cappellano; Antonio Sérgio Petrilli; Ana Marisa Chudzinski-Tavassi; Sérgio Cavalheiro Journal: Oncotarget Date: 2018-04-24